SOUTH SAN FRANCISCO, Calif.--(BUSINESS WIRE)--May 14, 2019--
Inc. (Nasdaq: VCYT), a leading genomic diagnostics company, today
announced that it has named Sangeeta Bhorade, M.D., medical director of
pulmonology. In this role, Dr. Bhorade will lead medical affairs for
Veracyte’s pulmonology products, including the Percepta®
Bronchial Classifier and Envisia™ Genomic Classifier. Dr. Bhorade will
report to Giulia Kennedy, Ph.D., Veracyte’s chief scientific and medical
Prior to joining Veracyte, Dr. Bhorade was professor of medicine and the
medical director of the Lung Transplant Program in the Pulmonary and
Critical Care Division at Northwestern University Feinberg School of
Medicine. During her tenure at Northwestern University, Dr. Bhorade
launched its Lung Transplant Program and provided research and clinical
expertise as a principal faculty member of the Interstitial Lung Disease
Program. She also initiated the Lung Transplant Program at the
University of Chicago and served as its medical director.
“We are thrilled to welcome Sangeeta to the Veracyte team,” said Bonnie
Anderson, Veracyte’s chairman and chief executive officer. “As a leader
in the field of pulmonology, she brings a wealth of expertise and
experience to our pulmonary program and will be instrumental in helping
us advance early detection, improve diagnosis and inform treatment
decisions for patients.”
“I am excited to join Veracyte and provide clinical and research
expertise to help shape the company’s portfolio of pulmonary
diagnostics,” said Dr. Bhorade. “I look forward to helping patients get
access to these scientifically advanced tests that may help improve
their health outcomes and cost of care."
Dr. Bhorade is board certified in pulmonary and critical care medicine.
She received her B.A. from the University of Chicago and her medical
degree from the University of Chicago Pritzker School of Medicine. Dr.
Bhorade has been voted a “Top Doctor” in pulmonology by U.S. News and
World Report for the past seven years.
Veracyte (Nasdaq: VCYT) is a leading genomic diagnostics company that
improves patient care by providing trustworthy and actionable answers to
challenging clinical questions. The company's products uniquely combine
advanced genomic technology, clinical science and machine learning to
provide answers that give physicians and patients a clear path forward,
informing both diagnosis and treatment decisions without the need for
costly, risky surgeries that are often unnecessary. Since its founding
in 2008, Veracyte has commercialized five genomic tests, which are
transforming the diagnosis of thyroid cancer, lung cancer and idiopathic
pulmonary fibrosis. Veracyte is based in South San Francisco,
California. For more information, please visit www.veracyte.com
and follow the company on Twitter (@veracyte).
Veracyte, Afirma, Percepta, Envisia and the Veracyte logo are trademarks
of Veracyte, Inc.
View source version on businesswire.com: https://www.businesswire.com/news/home/20190514005390/en/
Source: Veracyte, Inc.
Investor and Media Contact:
Angie McCabe, 650-243-6371
President, Investor Relations and Corporate Communications